摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-氟苯氧基)苯酚 | 1524-19-2

中文名称
4-(4-氟苯氧基)苯酚
中文别名
——
英文名称
4-(4-fluorophenoxy)phenol
英文别名
——
4-(4-氟苯氧基)苯酚化学式
CAS
1524-19-2
化学式
C12H9FO2
mdl
MFCD00792448
分子量
204.201
InChiKey
KIVFDFJTCRMULF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    94-98 °C
  • 沸点:
    311.0±27.0 °C(Predicted)
  • 密度:
    1?+-.0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xn,N
  • 安全说明:
    S26
  • 危险类别码:
    R22
  • 海关编码:
    2909500000
  • 危险品运输编号:
    UN 3077 9/PG 3

SDS

SDS:4a1745b5905a4e3556f3f97124862c9f
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-(4-Fluorophenoxy)phenol
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Fluorophenoxy)phenol
CAS number: 1524-19-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H9FO2
Molecular weight: 204.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(4-氟苯氧基)苯酚甲胺 、 potassium iodide 作用下, 以 乙醇 为溶剂, 反应 1.0h, 以72.6%的产率得到2-iodo-4-(4-fluorophenoxy)phenol
    参考文献:
    名称:
    Synthesis and biological evaluation of XB-1 analogues as novel histamine H3 receptor antagonists and neuroprotective agents
    摘要:
    一类新型H3受体拮抗剂——基于苯并酮或氧二苯结构的XB-1类似物被合成,并评估了它们的生物活性,以确定它们对Aβ25–35诱导的原代皮层神经元损伤和谷氨酸诱导的原代小脑颗粒神经元损伤的体外神经保护作用。结果表明,所有测试的类似物在0.1 μM或1 μM浓度下均显示出神经保护活性。这些发现可能为开发具有潜在神经保护活性新型有前景的H3受体拮抗剂提供新思路。
    DOI:
    10.1039/c3ra46392c
  • 作为产物:
    描述:
    1-氟-4-(4-甲氧基苯氧基)苯氢溴酸溶剂黄146 作用下, 反应 16.0h, 以72.9%的产率得到4-(4-氟苯氧基)苯酚
    参考文献:
    名称:
    Synthesis and biological evaluation of XB-1 analogues as novel histamine H3 receptor antagonists and neuroprotective agents
    摘要:
    一类新型H3受体拮抗剂——基于苯并酮或氧二苯结构的XB-1类似物被合成,并评估了它们的生物活性,以确定它们对Aβ25–35诱导的原代皮层神经元损伤和谷氨酸诱导的原代小脑颗粒神经元损伤的体外神经保护作用。结果表明,所有测试的类似物在0.1 μM或1 μM浓度下均显示出神经保护活性。这些发现可能为开发具有潜在神经保护活性新型有前景的H3受体拮抗剂提供新思路。
    DOI:
    10.1039/c3ra46392c
点击查看最新优质反应信息

文献信息

  • Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors
    作者:Yoshitaka Satoh、James L. Stanton、Alan J. Hutchison、Adam H. Libby、Timothy J. Kowalski、Warren H. Lee、D. Hope White、Earl F. Kimble
    DOI:10.1021/jm00075a013
    日期:1993.11
    A series of chromene derivatives was synthesized and evaluated for their in vitro and ex vivo 5-lipoxygenase (5-LO) inhibitory activity. These compounds were prepared by condensation of appropriate salicyl aldehydes with alpha, beta-unsaturated carbonyl compounds, followed by transformation to the corresponding hydroxamic acids or N-hydroxyureas. Placement of phenoxy or p-fluorophenoxy substituents
    合成了一系列色烯衍生物,并对其体外和离体的5-脂氧合酶(5-LO)抑制活性进行了评估。这些化合物的制备方法是将适当的水杨醛与α,β-不饱和羰基化合物缩合,然后转化为相应的异羟肟酸或N-羟基脲。如豚鼠PMN 5-LO测定所表明的,将苯氧基或对氟苯氧基取代基放置在亚甲基环的6位上导致体外效能的显着提高。通常,在离体狗模型中,二氯异羟肟酸的性能较差。另一方面,用N-羟基脲代替异羟肟酸的功能在狗模型中产生了有效且持久的5-LO抑制剂。在大多数情况下,色烯N-羟基脲的口服功效与其体外活性非常相关。化合物43(CGS 23885)和55(CGS 24891)是制备的最有效的抑制剂,其IC50值分别为48和51 nM。静脉内(iv)给药1.0 mg / kg后,化合物43和55的作用持续时间(DA)值分别为21和20 h。在口服(po)实验中,以1.0 mg / kg的剂量,43和55的DA分别为14和15
  • 核苷磷酰胺类化合物及其制备方法和药物中 的应用
    申请人:四川科伦博泰生物医药股份有限公司
    公开号:CN106554382B
    公开(公告)日:2019-12-03
    本发明提供一种式(I)所示的核苷磷酰胺类化合物,以及所述化合物作为抗病毒药物的用途。本发明的式(I)化合物能够抑制RNA病毒的复制、可作为丙型肝炎病毒(HCV)NS5B聚合酶的抑制剂。本发明的化合物在具有NS5B聚合酶抑制作用的同时,其对肝细胞的毒性小。
  • LTA4 Hydrolase inhibitors
    申请人:G.D. SEARLE & CO.
    公开号:EP1221441A2
    公开(公告)日:2002-07-10
    The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.
    本发明提供了具有公式Ar1-Q-Ar2-Y-R-Z的化合物及其药用可接受的盐,其中Ar1和Ar2是可选地取代的芳基部分,Z是可选地取代的含氮部分,可以是环状、环状或双环状的胺,或可选地取代的单环或双环的含氮杂芳基部分;Q是能够连接两个芳基团的连接基团;R是烷基亚基;Y是能够连接芳基团和烷基亚基的连接基团,并且其中Z通过氮原子与R键合。本发明的化合物和药物组合物在治疗由LTB4产生介导的炎症性疾病中是有用的,例如银屑病、溃疡性结肠炎、炎症性肠病和哮喘。
  • Tetrazolylpropan-2-ones as inhibitors of fatty acid amide hydrolase: Studies on structure-activity relationships and metabolic stability
    作者:David Garzinsky、Stefan Zahov、Merlin Ekodo Voundi、Walburga Hanekamp、Matthias Lehr
    DOI:10.1016/j.ejmech.2018.10.021
    日期:2018.12
    A series of derivatives of 1-(4-octylphenoxy)-3-(2H-tetrazol-2-yl)propan-2-one (3) and 1-(4-octylphenoxy)-3-(1H-tetrazol-1-yl)propan-2-one (4) was synthesized and tested for fatty acid amide hydrolase (FAAH) inhibitory potency and phase I metabolic stability. Introduction of certain substituents like 4-chlorophenyl, 4-methoxycarbonylphenyl and carboxyl in position 5 of the tetrazole ring of 3 led to
    1-(4-辛基苯氧基)-3-(2 H-四唑-2-基)丙-2-酮(3)和1-(4-辛基苯氧基)-3-(1 H-四唑-合成了1-yl)prop-2--2-(4)并测试了脂肪酸酰胺水解酶(FAAH)的抑制能力和I期代谢稳定性。在3的四唑环的5位上引入某些取代基(如4-氯苯基,4-甲氧基羰基苯基和羧基)可显着提高易裂解酮药效基团的代谢稳定性,而对FAAH的高活性并未受到明显影响。相反,在杂环系统4的5位上的取代基对不希望的酮还原没有显着影响。此外,通过在丙烷-2-一骨架的3位上的甲基取代基来屏蔽一些3的衍生物的酮基的效果以及这些化合物的亲脂性辛基残基被更多的类药物取代基取代的结果是检查。
  • 5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists
    作者:Hiroo Koyama、Julia K Boueres、Wei Han、Edward J Metzger、Jeffrey P Bergman、Dominick F Gratale、Daniel J Miller、Richard L Tolman、Karen L MacNaul、Joel P Berger、Thomas W Doebber、Kwan Leung、David E Moller、James V Heck、Soumya P Sahoo
    DOI:10.1016/s0960-894x(03)00257-9
    日期:2003.5
    A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.
    设计,合成了一系列含有4-苯氧基苯基侧链的5-芳基噻唑烷-2,4-二酮,并评估了其PPAR激动剂的活性。一种这样的化合物28在db / db小鼠2型糖尿病动物模型中显示出与罗格列酮相当的葡萄糖校正水平。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐